Share this page!

Maybe Scrolly?
Aaysha Cader 🫀 Profile picture
Twitter logo
4 Dec, 7 tweets, 24 min read
Dominick Angiolillo on the dilemma of perioperative antiplatelet therapy
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela @cristina_gavina
Some great insights on limitations of perioperative antiplatelet Rx & limitations of guidelines - the issue perioperative antiplatelet and HBR are not the same! #CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @DrRajivsankar @FaiezZANNAD @DLBHATTMD
Basic concepts on bridging antiplatelets and why #cangrelor is best suited
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @mirvatalasnag @SuzanneJBaron @DLBHATTMD @Pooh_Velagapudi @sabeedak1 @SABOURETCardio
Ticagrelor Revseral : Bentracimab and the REVERSE-IT trial
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @hvanspall @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela @mirvatalasnag @ShrillaB
Next, @georgedangas tackles Bridging Antiplatelet Therapy with #Cangrelor - "Fast-on fast-off" is most important property of an ideal bridging antiplatelet
#CVCT2021 @CVCTForum @SantosGallegoMD @AHajduczok @DrRaniKhatib @FaiezZANNAD @drdargaray @SolovevaAnzhela @DLBHATTMD
When and how do you bridge and switch? Expert consensus recommendations @georgedangas #CVCT2021 @CVCTForum @SantosGallegoMD @AHajduczok @DrRaniKhatib @FaiezZANNAD @drdargaray @SolovevaAnzhela @DLBHATTMD @DrRajivsankar @hvanspall @mirvatalasnag @docbhardwaj @Sarah_Moharem
Robert Storey details the Cytosorb system: Extracorporeal blood purification from antithrombotic agents:a novel paradigm for the removal of ticagrelor?
#CardioEd #CVCT2021 @CVCTForum @SantosGallegoMD @AHajduczok @DrRaniKhatib @FaiezZANNAD @drdargaray @SolovevaAnzhela @DLBHATTMD

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Aaysha Cader 🫀

Aaysha Cader 🫀 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @aayshacader

Aaysha Cader 🫀 Profile picture
4 Dec
Such an important topic!Sex-related eligibility criteria leading to exclusion of women from clinical trials. @hvanspall proposes pragmatic eligibility criteria facilitating enrolment of women &URM in RCTs
#CVCT2021 @CVCTForum @SantosGallegoMD @DrRaniKhatib @drdargaray
Brilliant slide by @hvanspall on strategies to increase diversity in clinical trials
#CVCT2021 @CVCTForum @docbhardwaj @SantosGallegoMD @AHajduczok @DrRaniKhatib @Drroxmehran @DrRajivsankar @rachkataria @FaiezZANNAD @drdargaray @ShahzebKhanMD @DVervoort94 @SolovevaAnzhela
@FaiezZANNAD on geographic equity in CV clinical trials:increasing research capacity & trial enrolment in LMIC Case in point:MENA region
#CVCT2021 @CVCTForum @docbhardwaj @DjawidHashemi @DrRaniKhatib @hvanspall @DrRajivsankar @drdargaray @DVervoort94 @mirvatalasnag @Hragy
Read 17 tweets
Aaysha Cader 🫀 Profile picture
4 Dec
The regulatory viewpoint of endpoints in antithrombotic therapy trials by Ellis Unger #CVCT #iCVCT @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok @Drroxmehran @djc795 @A_FelixOliveira
The regulatory viewpoint of endpoints in antithrombotic therapy trials by Ellis Unger #CVCT2021 @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok @DjawidHashemi @BoldiKovacsMD @ZainabDakhil2
How different should anti XIa trials be: @CMichaelGibson weighs in on population, endpoints, duration of therapy, disease states?
#CVCT2021 @docbhardwaj @DrRajivsankar @DrRaniKhatib @SantosGallegoMD @CMichaelGibson @hvanspall @CVCTForum @rachkataria @lucreciamburgos @AHajduczok
Read 4 tweets
Aaysha Cader 🫀 Profile picture
3 Dec
#ICPeeps next up: the first session of #iCVCT #CVCT2021 on hemodynamic support trials with ⭐ panel
@alaide_chief @NavinKapur4 @thiele_holger @georgedangas et al.

@CVCTForum @Drroxmehran @CMichaelGibson @mirvatalasnag @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @ShrillaB
Despite ESC recommendations IABP remains most widely used MCS in Germany: European perspectives and trends in MCS by @alaide_chief
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @ShrillaB @Babar_Basir @adityadoc1 @DrRaniKhatib @docbhardwaj
Heterogenic use of #MCS in Europe dictated by country specific policies, cost and availability
@alaide_chief
#CVCT #iCVCT @NavinKapur4 @thiele_holger @georgedangas @CVCTForum @Drroxmehran @hvanspall @rachkataria @AHajduczok @DrRajivsankar @DrRaniKhatib @SantosGallegoMD
Read 10 tweets
Aaysha Cader 🫀 Profile picture
2 Dec
fantastic takeaway slides on subgroup analyses & secondary results publications by @FaiezZANNAD
#CVCT2021 @hvanspall @DjawidHashemi @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray ImageImage
Dr Joseph Hill @CircAHA on the nuances and challenges with publishing artificial intelligence analyses of trial databases:
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @DrRajivsankar @cristina_gavina @A_FelixOliveira @BoldiKovacsMD @docbhardwaj @drdargaray ImageImageImage
@cardiobrief Larry Husten raises an important issue; should trials be released to the press before full publication is available?
#CVCT2021 @hvanspall @rachkataria @SantosGallegoMD @AlexNowbar @CVCTForum @drdargaray @DrRajivsankar @DrRaniKhatib @AHajduczok
Read 5 tweets
Aaysha Cader 🫀 Profile picture
30 Aug
#ESCCongress When coronary angiography is not enough: @RaberLorenz turns on the light with #OCT –
🔦ACS-⬆️resolution of OCT -gold standard to ID thrombus, ID unclear culprit, ACS aetiology, rule-in & rule-out
🔦#MINOCA
🔦Stent thombosis
🔦Optimize PCI
@mirvatalasnag @Hragy
Phenomenal talk oy @MaeharaAkiko : SCenarios where #IVUSis gold-standard

#ESCCongress @sbrugaletta @ziadalinyc @SanjogKalra @NishithChandra @APSIC6 @w_jyg @DrAnkushG @care4urheart2 @ShrillaB @chadialraies @cardioPCImom @ANazmiCalik @GeminaDB @KVM83 @ShaziaTHussain1
#ESCCongress
@JEscaned on physiologic assessment in guiding PCI

@adityadoc1 @DrAllenJ @SukhNijjer @Pooh_Velagapudi @adityadoc1 @poojaotherwise @KardiologieHH @w_jyg @NishithChandra @sabeedak1 @SanChris999 @skilicmd @APSIC6 @chadialraies @dranulala @Ortega_Paz @sbrugaletta
Read 6 tweets
Aaysha Cader 🫀 Profile picture
20 May
#EuroPCR Physiology-guided imaging case of stagedPCI to RCA in a patient with MVD from Imperial
- now in the Main Arena
@rallamee @SukhNijjer

@ANazmiCalik @ShaziaTHussain1 @ShrillaB @TharushaGunawa4 @NicolaRyanI1 @AsherElad @Ortega_Paz @ezmanshariff @DrAllenJ @mirvatalasnag
#EuroPCR Setting up the Omniwire for physiologic assessment

@PCRonline
#EuroPCR @PCRonline
Recording normalization ⤵️
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @aayshacader has new unrolls!

Check out other threads from @aayshacader!

Read all threads by @aayshacader

:(